GABA Receptor Baclofen, (±)-Baclofen, (RS)-Baclofen CAS 1134-47-0

Basic Info

Model No.: 1134-47-0

Additional Info

Packaging: AS REQUIRED

Productivity: KGS

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: TRUE MANUFACTURER

Certificate: ISO

Product Description

Baclofen CAS 1134-47-0, also known as (±)-Baclofen and (RS)-Baclofen, is a GABA receptor agonist which is primarily used to treatment of spasticity, is also used in topical pain creams as a muscle relaxant, and is a central nervous system depressant used as a skeletal muscle relaxant.
Baclofen CAS NO 1134-47-0 is high specification which standard reach USP38, EP 7.0 and BP 2010 demand. Baclofen 1134-47-0 is white powder, which moisture content is less than 0.3% and the residue on ignition is also less than 0.02%. The residual solvent of Baclofen by GC is below percent 0.08, and the purity by HPLC is more than percent 99.5. Our monthly capacity is 2 to 3 tons, and have certain inventory. If you are interested in our Baclofen, please contact us freely. 

Thera. Category: Antispasmodics

Cas No.: 1134-47-0

Synonym:Baclofen, (±)-Baclofen, (RS)-Baclofen -(Aminomethyl)-4-chlorobenzenpropanoicacid;-(p-Chlorophenyl)-aminobutyricacid;ba34647;baclon;beta-(4-chlorophenyl)gaba;beta-(aminomethyl)-4-chloro-benzenepropanoicaci;beta-(aminomethyl)-p-chloro-hydrocinnamicaci;beta-(aminomethyl)-p-chlorohydrocinnamicacid

Molecular Formula:C10H12ClNO2

Molecular Weight:213.66

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request 

Usage: Baclofen 1134-47-0  is a γ- aminobutyric acid derivative. It is an antispasmodics class drugs acting on the central nervous system, the brain and spinal cord as a skeletal muscle relaxants and sedatives. It take antispasmodic effect by stimulating receptors to inhibit the release of excitatory amino acids such as glutamic acid, aspartic acid and thereby inhibiting the transfer of single and multi-synaptic reflex in central nervous system, brain and spinal cord. Clinically it has already been used as racemic agent for treating Muscle spasticity since mid-1960s. Recent studies have also found that this product can significantly reduce the symptoms of gastroesophageal reflux and alleviating related symptoms. It can also alleviate the dystonia of children and treat the urination dysfunction caused by central spinal cord injury. In addition, the intrathecal injection therapy of the product in clinical application can further improve the clinical efficacy, and make it possible to adjust drugs dosage which stabilizes the treatment effect. For the past 10 years, the clinical application of central muscle relaxant baclofen has made significant progress, particularly in accumulating a lot of experiences in the neurological rehabilitation treatment of reducing muscular tension and pain alleviation treatment.